Oncolytics Biotech Files Routine 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Nov 12, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting, foreign-private-issuer, sec-filing
TL;DR
Oncolytics Biotech filed a standard 6-K, no major news.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on November 12, 2025, reporting for the period ending September 30, 2025. The company, based in Calgary, Canada, is a foreign private issuer and is submitting its report under the 1934 Securities Exchange Act. This filing is routine and does not appear to contain specific financial results or material events for this period.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is meeting its reporting obligations as a foreign private issuer, which is standard for companies trading on US exchanges.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not disclose new material information or financial results.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- November 12, 2025 (date) — Filing Date
- September 30, 2025 (date) — Reporting Period End Date
- Calgary, Canada (location) — Company Headquarters
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of November 2025.
What period does this filing cover?
The Conformed Period of Report is 20250930, meaning it covers the period ending September 30, 2025.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc. is located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Is Oncolytics Biotech Inc. filing an annual report with this form?
The filing indicates whether the registrant files annual reports under Form 20-F or Form 40-F. A checkmark is present next to Form 20-F, indicating it files annual reports under that form.
What is the Commission File Number for this filing?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2025-11-12 17:28:54
Filing Documents
- q32025form6-k.htm (6-K) — 22KB
- ex991-interimfsseptember30.htm (EX-99.1) — 409KB
- ex992-q32025mda.htm (EX-99.2) — 251KB
- ex993-q32025certificationx.htm (EX-99.3) — 14KB
- ex994-q32025certificationx.htm (EX-99.4) — 14KB
- oncolyticslogotaglineblueaa.jpg (GRAPHIC) — 347KB
- 0001129928-25-000089.txt ( ) — 1139KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) Date November 12, 2025 By s Kirk Look Kirk Look Chief Financial Officer